Cumulative probability of high-grade dysplasia, pancreatic ductal adenocarcinoma 26 percent at 10 years in high-risk individuals with MPD dilation ...

Funding accounted for 34.5 percent of total financial assistance requested in campaigns initiated between Jan. 1, 2021, and Feb. 28, 2023.

Topline data were announced from a phase 3 trial evaluating giredestrant for the adjuvant treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ...

In this cross-sectional analysis, researchers aimed to characterize the NIH trials affected by grant terminations under the Trump administration.

The phase 2 ChonDRAgon study compared ozekibart to placebo in patients with metastatic or unresectable conventional chondrosarcoma who been diagnosed with radiographic progression.